Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain.

Miguel Angel CallejaJoan AlbanellEnrique ArandaJesús García-FoncillasAnna FeliuFernando RiveraItziar Oyagüez Laura Salinas-OrtegaJavier Soto Alvarez

Published in: European journal of hospital pharmacy : science and practice (2021)

The introduction of biosimilars in the Spanish Health System would generate saving costs in the pharmacological budget to boost biological drugs from the first year.

Keyphrases